文献速递艾滋病与性传播感染医院感染防控

二价HPV疫苗对女性肛门口HPV阳性的效果

Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands.
PubMed 文献 · J Infect Dis · 2020-01-01

该研究在荷兰548名16-24岁女性STI门诊就诊者中开展重复横断面调查,估计二价HPV疫苗至少1剂对肛门口HPV阳性的疫苗有效性。结果显示,针对HPV-16/18的疫苗有效性为89.9%(95%CI 63.0%-97.2%),型别特异性疫苗有效性与宫颈阴道HPV疫苗有效性高度相关(Spearman ρ=0.76)。

要点

  • 二价HPV疫苗至少1剂对肛门口HPV-16/18阳性的疫苗有效性为89.9%。
  • 型别特异性疫苗有效性与宫颈阴道HPV疫苗有效性相关(Spearman ρ=0.76)。
  • 提示HPV-16/18疫苗接种对生殖道和肛门感染的效果可能相当。

核心结论

  • 二价HPV疫苗至少1剂对16-24岁女性STI门诊就诊者肛门口HPV-16/18阳性具有较高疫苗有效性。

研究设计与样本

  • 重复横断面调查,纳入548名16-24岁女性STI门诊就诊者,均提供肛拭子样本。

主要发现

  • 至少1剂二价疫苗对肛门口HPV-16/18阳性的疫苗有效性为89.9%(95%CI 63.0%-97.2%)。
  • 型别特异性疫苗有效性与宫颈阴道HPV疫苗有效性高度相关(Spearman ρ=0.76)。

关键数值与推荐

  • 疫苗有效性定义为至少1剂二价疫苗对肛门口HPV阳性的效果。
  • HPV-16/18与约90%的HPV相关肛门癌相关。

临床怎么用

  • 支持将二价HPV疫苗接种作为女性肛门HPV感染及肛门癌预防的参考依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Woestenberg PJ, King AJ, Van Benthem BHB, et al. Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands. J Infect Dis. 2020. PMID: 31100134. doi:10.1093/infdis/jiz187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。